US 12,448,653 B2
Circulating serum microRNA biomarkers and methods for Parkinson's disease prognosis
Simon Geir Moller, Queens, NY (US); Indranil Basak, Queens, NY (US); Ketan Patil, Queens, NY (US); Jan Petter Larsen, Queens, NY (US); and Guido Werner Alves, Queens, NY (US)
Assigned to ST. JOHN'S UNIVERSITY, Queens, NY (US)
Filed by ST. JOHN'S UNIVERSITY, Queens, NY (US)
Filed on Aug. 21, 2023, as Appl. No. 18/452,778.
Application 18/452,778 is a division of application No. 16/623,870, granted, now 11,739,384, previously published as PCT/US2018/036380, filed on Jun. 7, 2018.
Claims priority of provisional application 62/521,797, filed on Jun. 19, 2017.
Prior Publication US 2024/0018595 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 10 Claims
 
1. A method for treating a human patient with rapid progressing Parkinson's disease, comprising the steps of, in this order:
obtaining a first sample comprising serum, plasma or blood from said patient;
determining a level of expression of at least one miRNA selected from the group consisting of SEQ ID NOS: 33, 42 and 45, and optionally further determining a level of expression of at least one miRNA selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 43, 44, 46, 47, 48, 49, 50, 51 and 52 within said first sample;
comparing the level of expression of the determined SEQ ID NOS to a level of expression of the determined SEQ ID NOS in a second sample from a cohort with slow progressing Parkinson's disease and confirming the expression level of the determined SEQ ID NOS in said first sample is greater than 1.2-fold over that of said second sample, thereby indicating the patient has rapid progressing Parkinson's disease; and
treating said rapid progressing Parkinson's disease with at least one of L-dopa, a dopamine agonist, a catechol-O-methyltransferase (COMT) inhibitor, amantidine (1-Aminotricyclo (3,3,1,13,7) decane or a monoamino oxidase type B inhibitor.